Extended Data Figure 9: GaMD immune serum from wild-type mice inhibits GaMD-induced renal disease without decreasing other isotypes if injected into GaMD-immunized γ1− mice by 5 days after immunization.
From: IgG1 protects against renal disease in a mouse model of cryoglobulinaemia
a, BALB/c γ1− mice (4 or 8 per group) were injected s.c. with GaMD on day 0 and i.p. with 0.5 ml of pooled serum from GaMD-immunized wild-type mice (GaMD immune WT serum) or unimmunized wild-type mice (non-immune serum), starting 4, 5 or 6 days after GaMD immunization. Day 7 urine samples were analysed. LE, leukocyte esterase; ND, none detected. b, BALB/c γ1− mice (4 or 8 per group) were injected s.c. with GaMD on day 0 and i.p. with 0.5 ml of pooled serum from GaMD-immunized wild-type mice (GaMD immune WT serum) or unimmunized wild-type mice (non-immune serum), 5, 6 and 7 days after GaMD immunization. Sera were assayed for total IgG1, IgG2a, IgM and IgG3 on day 0 (unimmunized) and 8 days after GaMD immunization. ND, none detected. *P < 0.05, **P < 0.005 (both as compared to day 6 only in a and unimmunized in b).
